ADMA Biologics (NASDAQ:ADMA) Announces Earnings Results

ADMA Biologics (NASDAQ:ADMA) posted its earnings results on Wednesday. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.20 by $0.03, FiscalAI reports. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $141.10 million during the quarter, compared to analysts’ expectations of $138.11 million. During the same quarter in the prior year, the firm earned $0.15 EPS. ADMA Biologics’s quarterly revenue was up 5.1% on a year-over-year basis.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV drove growth: Revenue rose 31% year over year to $124.7 million, with management citing broader physician adoption, new patient starts, and continued pull-through. The company said primary immunodeficiency remains the main growth driver, while uptake in secondary immunodeficiency has been more moderate.
• Profitability and outlook improved: Gross margin reached 71%, and adjusted EBITDA grew 32% year over year to $77.3 million. ADMA maintained its 2026 revenue outlook of at least $530 million while raising minimum adjusted EBITDA guidance to $275 million and adjusted net income guidance to $180 million.
• BIVIGAM remained under pressure: Revenue fell to $15.4 million from $19.4 million in the second quarter and $23.8 million a year earlier, amid pricing and channel competition. Management noted signs of utilization stabilization entering the fourth quarter but said discounting pressures persist.
• Share repurchases continued at scale: ADMA repurchased $181.4 million of stock in the first nine months, buying back 16.5 million shares, or about 6.3% of year-end 2025 shares outstanding. The company reiterated its target of at least $200 million in repurchases for 2026.
• SG-001 advanced, but timing remains uncertain: The FDA provided constructive pre-IND feedback on the candidate’s proposed clinical strategy and assay, and ADMA plans to incorporate recommendations into its IND preparations. Management did not provide a filing timeline and expects higher fourth-quarter R&D spending as it produces conformance lots.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock traded up $2.58 on Thursday, hitting $13.05. The company had a trading volume of 1,753,292 shares, compared to its average volume of 4,115,976. The business has a 50-day simple moving average of $10.07 and a 200-day simple moving average of $10.93. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The company has a market cap of $2.92 billion, a PE ratio of 18.44 and a beta of 0.65. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Mizuho set a $18.00 target price on ADMA Biologics in a research report on Thursday. Cantor Fitzgerald lifted their target price on ADMA Biologics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday, September 14th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus estimate, while adjusted EPS of $0.23 topped the $0.20 forecast. Revenue grew 5% year over year, and GAAP net income rose 37% to $49.9 million. ADMA Biologics Q3 results
• Positive Sentiment: ASCENIV revenue climbed 31% to $124.7 million, and gross margin expanded to 71% from a year earlier, supporting improved profitability and operating leverage. Q3 earnings and ASCENIV coverage
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. ADMA outlook update
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but kept a neutral rating, signaling a higher valuation objective without a more bullish analyst stance. Cantor Fitzgerald recommendations

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.